Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NMT Medical Inc.

www.nmtmedical.com

Latest From NMT Medical Inc.

Positive Long-Term Data Plug Doubts Over PFO-Closure Stroke Benefits

Data from the REDUCE, CLOSE, and RESPECT trials, published in the New England Journal of Medicine, showed that closing a patent foramen ovale with a percutaneous closure device can reduce the risk of ischemic stroke in patients who have already had a cryptogenic stroke. Observers believe these trials showed a benefit of PFO closure in this population after previous trials failed to show a benefit largely because they did a better job of only selecting patients most likely to benefit.

Cardiovascular Cardiology

Gore's PFO Closers REDUCE Recurrent Ischemic Strokes By 77% In Trial

REDUCE is the first trial of patent foramen ovale closure device to show statistically significant reduction in stroke recurrence in its primary intent-to-treat analysis. The results, presented at the European Stroke Organisation Conference in Prague, will support Gore's application for Cardioform to the US FDA by the end of the year.

Cardiology Clinical Trials

Advisors Provide Lukewarm Endorsement Of St. Jude's PFO Occluder For Stroke

FDA's Circulatory System Devices Panel said that St. Jude's Amplatzer PFO closure device has benefits that outweigh risks to prevent recurrent stroke in a select group of patients on an 11-5 vote, despite having missed its primary endpoint in the pivotal RESPECT trial.

Medical Device Regulation

St. Jude Hopes Its PFO Occluder Gets RESPECT At May FDA Panel

St. Jude won a May panel date for its Amplatzer patent foreman ovale occluder PMA, seeking approval to prevent recurrent stroke. It's been a challenging path to this point after the firm's pivotal RESPECT trial did not meet its primary endpoint in 2012.

Medical Device Regulation
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Nitinol Medical Technologies Inc.
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • NMT Medical Inc.
  • Senior Management
  • Contact Info
  • NMT Medical Inc.
    Phone: (617) 737-0930
    27 Wormwood St.
    Boston, MA 02210-1625
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register